PLRX
Pliant Therapeutics Inc

1,838
Mkt Cap
$71.9M
Volume
729,418.00
52W High
$3.78
52W Low
$1.09
PE Ratio
-0.41
PLRX Fundamentals
Price
$1.16
Prev Close
$1.17
Open
$1.18
50D MA
$1.28
Beta
1.46
Avg. Volume
1.03M
EPS (Annual)
-$3.47
P/B
0.36
Rev/Employee
$0.00
$501.76
Loading...
Loading...
News
all
press releases
Pliant Therapeutics (NASDAQ:PLRX) CEO Sells $114,400.00 in Stock
Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) CEO Bernard Coulie sold 89,375 shares of the business's stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at...
MarketBeat·19d ago
News Placeholder
More News
News Placeholder
Bernard Coulie Sells 89,375 Shares of Pliant Therapeutics (NASDAQ:PLRX) Stock
Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) CEO Bernard Coulie sold 89,375 shares of the firm's stock in a transaction on Tuesday, January 20th. The stock was sold at an average price...
MarketBeat·19d ago
News Placeholder
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Reduce" by Analysts
Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) has been assigned an average recommendation of "Reduce" from the fourteen ratings firms that are currently covering the stock, MarketBeat...
MarketBeat·1mo ago
News Placeholder
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Short Interest Down 20.3% in December
Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totaling...
MarketBeat·1mo ago
News Placeholder
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Reduce" by Brokerages
Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) has earned a consensus rating of "Reduce" from the fourteen ratings firms that are currently covering the firm, MarketBeat reports. Two...
MarketBeat·2mo ago
News Placeholder
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
Pliant Therapeutics posts interim Phase 1 data showing antitumor activity and durable responses for PLN-101095 in ICI-refractory advanced cancer patients.read more...
Benzinga·2mo ago
News Placeholder
Pliant Therapeutics (NASDAQ:PLRX) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen upgraded shares of Pliant Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday...
MarketBeat·3mo ago
News Placeholder
Pliant Therapeutics (NASDAQ:PLRX) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS
Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of...
MarketBeat·3mo ago
<
...
1
>

Latest PLRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.